Evaxion Biotech has announced preclinical data demonstrating the effectiveness of its AI-driven viral vaccine discovery platform.
The presented preclinical study was conducted in collaboration with associate professor Girish Kirimanjeswara, Pennsylvania State University, US.
Our RAVEN platform represents a paradigm shift in vaccine development, identifying vaccine candidates against any existing, newly emerging, and mutating viral diseases tailored to any human target population to secure broader and more durable protection.”
The published data showcase how Evaxion’s AI-platform, RAVEN (Rapidly Adaptive Viral Response), identifies broad and robust T-cell epitopes from SARS-CoV-2 that protect against mortality and severe disease in a COVID-19 mouse model. This research demonstrates the potential of the RAVEN platform to accelerate the development of effective viral vaccines, leveraging the power of artificial intelligence.
“Our RAVEN platform represents a paradigm shift in vaccine development, identifying vaccine candidates against any existing, newly emerging, and mutating viral diseases tailored to any human target population to secure broader and more durable protection,” says Birgitte Rønø, Chief Scientific Officer of Evaxion. “This positive preclinical data affirms our ability to select the right T-cell epitopes, ultimately resulting in better vaccines for patients. We remain committed to further advancing our AI-driven viral vaccine discovery platform and collaborating with key partners to translate our findings into tangible solutions for addressing global health challenges.”
RAVEN enables discovery of novel T-cell epitopes for any viral disease with the potential of enhancing the efficacy of new and existing B-cell vaccines and addresses the issues of fading efficacy and evasion for many viral vaccines.
Photo of Birgitte Rønø: Evaxion